Nephrology and Urology

  • Breastfeeding may reduce moms’ stroke risk

    on June 21st, 2017
    FROM THE JOURNAL OF THE AMERICAN HEART ASSOCIATION Breastfeeding not only benefits babies; it also may lower the risk for a heart attack or stroke later in life for mothers who breastfeed more than for women who don’t. The findings, which were published online June 21 in the Journal of the America[...]
  • PROTECT: Pazopanib falls short as adjuvant therapy for high-risk RCC

    on June 19th, 2017
    AT ASCO 2017 CHICAGO (FRONTLINE MEDICAL NEWS) – The antiangiogenic agent pazopanib is not efficacious when used as adjuvant therapy for resected renal cell carcinoma (RCC) with features that confer a high risk of recurrence, the PROTECT investigators reported at the annual meeting of the American [...]
  • Hypogonadism after testicular cancer treatment can have lifelong impact

    on June 14th, 2017
    AT ASCO 2017 CHICAGO (FRONTLINE MEDICAL NEWS) – Hypogonadism may compromise the long-term health outlook for many younger men who have been successfully treated for testicular cancer, according to an analysis conducted by the Platinum Study Group. “Today, 95% of all testicular cancer patients ar[...]
  • Should convicted sex offender get penile prosthetic implant?

    on June 9th, 2017
    AT APA SAN DIEGO (FRONTLINE MEDICAL NEWS) – Should a man with a distant history of pedophilia be allowed to get a penile prosthetic implant to treat his erectile dysfunction? Mental health professionals at a Veterans Affairs medical center in San Diego recently faced this question and decided the [...]
  • FDA panel backs licensure for epoetin alfa biosimilar

    on May 26th, 2017
    A Food and Drug Administration advisory committee voted overwhelmingly in support of licensure for Epoetin Hospira as a biosimilar product to epoetin alfa (Epogen/Procrit) for all approved Epogen/Procrit indications. Most committee members who voted “yes” said they were hesitant to do so, howeve[...]
  • Alternating therapy in renal cell carcinoma fails to show an advantage

    on May 17th, 2017
    FROM JAMA ONCOLOGY There was no efficacy or safety advantage for alternating everolimus with pazopanib over pazopanib alone in patients with metastatic or locally advanced clear cell renal cell carcinoma (ccRCC), according to a newly published randomized trial. The study hypothesis was that alternat[...]
  • FDA: Fluoroquinolone use not linked to retina detachment, aortic problems

    on May 11th, 2017
    The Food and Drug Administration has found no evidence of a link between fluoroquinolone usage and retinal detachment or aortic aneurysm and dissection, according to a new Drug Safety Communication update on potential serious, disabling side effects of oral and injectable fluoroquinolone antibiotics[...]
  • UTI predictors identified in infants under 3 months of age

    on May 9th, 2017
    AT PAS 17 SAN FRANCISCO (FRONTLINE MEDICAL NEWS) – Serum leukocytosis, pyuria, and urine leukocyte esterase have been identified as predictors of urinary tract infection (UTI) in infants younger than 90 days of age, with males being more likely to develop UTI than females. Fever and gestational ag[...]
  • Durvalumab approved for advanced urothelial carcinoma

    on May 2nd, 2017
    The Food and Drug Administration has granted accelerated approval to the checkpoint inhibitor durvalumab for patients with locally advanced or metastatic urothelial carcinoma who have disease progression after prior treatment with a platinum-containing chemotherapy. The agency also approved a comple[...]
  • Ultrasound, cystoscopy combo tops CT for asymptomatic microscopic hematuria

    on April 17th, 2017
    FROM JAMA INTERNAL MEDICINE Combining renal ultrasound and bladder cystoscopy is the most cost-effective approach for the initial evaluation of asymptomatic microscopic hematuria, even among patients at risk for genitourinary malignancy, according to a report published online April 17 in JAMA Intern[...]
  • MicroRNAs linked to treatment response in lupus nephritis

    on April 10th, 2017
    AT LUPUS 2017 MELBOURNE (FRONTLINE MEDICAL NEWS) – Researchers have identified six microRNAs that may indicate a better likelihood of response to cyclophosphamide in patients with lupus nephritis, according to a study presented at an international conference on systemic lupus erythematosus. “Mic[...]
  • Metformin linked with better survival in RCC patients with diabetes

    on April 10th, 2017
    Metformin use was associated with better survival for patients with renal cell carcinoma and diabetes in a meta-analysis, investigators report. Yang Li, MD, and associates at Chongqing (China) Medical University, performed a pooled analysis of data from 254,329 patients with both localized and metas[...]
  • Alpha-blockers deemed safe in heart failure

    on April 5th, 2017
    At ACC 17 WASHINGTON (FRONTLINE MEDICAL NEWS) – Prescribing alpha-adrenergic blocking agents for treatment of benign prostatic hypertrophy in men with heart failure proved to be not only safe, but also was associated with significantly reduced rates of both heart failure readmission and all-cause [...]
Back to top